久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

US EUROPE AFRICA ASIA 中文
Business / Companies

GSK puts China corruption case behind it, forms new business model

By Cecily Liu (chinadaily.com.cn) Updated: 2015-10-22 20:17

GSK puts China corruption case behind it, forms new business model

The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai in this July 12, 2013 file photo.[Photo/Agencies]

GlaxoSmithKline emerged from its corruption scandal in China in 2013 to form a new business model in the country and is committed to further expansion there, chief executive officer Andrew Witty told China Daily in London on Wednesday in an exclusive interview.

"We think it's a very sad and disappointing experience, but we've reacted constructively and learnt many things. And now we understand China better, we have a new commercial model and incentive system, which is in step with the expectations of the Chinese government," Witty said.

In 2013, GSK was found by the Chinese authorities to be bribing doctors to prescribe its drugs to patients, and after a court trial the company was made to pay a $489 million fine in 2014.

Witty said that GSK has since developed a commercial model with improved technology and transparency.

The transparency of the model allows GSK to monitor its sales staff to make sure no bribe is paid to doctors, and the continuously improving technology allows doctors to obtain much more information about GSK drugs to aid their decision making process when prescribing medicine.

"We've made it clear to the doctors in China about our changes and have spent a great deal of time to explain to them the reasons for us making the changes. We have received a lot of understanding and appreciation from doctors about our approach," Witty said.

As well, GSK has invested in continuously improving technology to reduce the cost of the medicine, Witty said.

Speaking about China's healthcare market environment, Witty said that China is a country that it takes time to understand, just like any other country, and understanding China encompasses its economic policies, economic direction and regulation.

He said that "GSK is lucky to be a guest of China" and will fulfill its responsibility to deliver the medicine that are up to expectations.

GSK also announced on Wednesday that it will invest 2 million pounds in a 3 year partnership with the National Health and Family Planning Commission of China to train seven thousand Chinese doctors in the diagnosis and treatment of Hepatitis B.

Witty said that this investment reaffirms GSK's long term commitment to serving China and the healthcare needs of patients in the country.

Hepatitis B is a high priority in China, with about 20 million sufferers across the country remaining untreated.

"We think it is important that we're doing the training in partnership with the Chinese government, so that we can make sure what we have invested in will help to address issues that are of real importance to China," said Witty.

He said that the Hepatitis B investment is similar to GSK's investment into training Chinese doctors in the treatment of respiratory conditions and chronic obstructive pulmonary disease, announced last month, which are also healthcare priority areas identified by the government.

The Hepatitis B program, to be run over three years, and delivered by the Development Center for Medical Science and Technology, National Health and Family planning Commission of China, will help doctors understand how to diagnose, treat and provide ongoing management to patients with Hepatitis B.

Witty said that China will remain important to GSK over the long term, in particular because it has a large population, meaning that from a commercial perspective the sales potential is great, and from a research perspective it can provide a valuable environment to develop medicine that GSK can use globally.

GSK was ranked as the world's sixth-largest pharmaceutical company in 2014, with revenue of 23 billion pounds.

GSK has already committed 6 million pounds for public health initiatives in China over the next five years, with around 4 million being spent on independent GP training, the company said in a statement.

To contact the reporter: cecily.liu@mail.chinadailyuk.com

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 全国男人的天堂网站 | 久久精品免看国产 | 萌白酱香蕉白丝护士服喷浆 | 成人伊人青草久久综合网 | 国产男女乱淫真视频全程播放 | 永久免费91桃色福利 | 中文字幕一区二区小泽玛利亚 | 欧美性色xo影院69 | 看一级特黄a大片国产 | 毛片久久久 | 韩国日本三级在线观看 | 中文字幕国产视频 | 91精品国产乱码久久久久久 | 成人精品一区二区久久久 | 欧美亚洲日本在线 | 国产成人免费观看 | 人人操美女 | 久久亚洲国产精品 | 国产成人久久一区二区三区 | 亚洲视频免费看 | 国产精品久久久久久久久免费观看 | 精品中文字幕久久久久久 | 男人桶女人逼 | 韩国免费a级毛片 | 婷婷色九月综合激情丁香 | 在线观看视频亚洲 | 操亚洲| 亚洲美女性视频 | 欧美色视频在线观看 | 欧美成人tv在线观看免费 | 成人免费视频日本 | 91精品国产91久久久久 | 欧美日韩一区二区综合 | 国产日本韩国不卡在线视频 | 午夜在线亚洲男人午在线 | 欧美精品不卡 | 99成人在线视频 | 看全色黄大色黄大片毛片 | 日本一级视频 | 中字毛片| 久久久亚洲精品蜜桃臀 |